Kyntra Bio

Yahoo Finance • 19 days ago

Kyntra Bio targets Q4 2026 interim readout while extending cash runway into 2028

Earnings Call Insights: Kyntra Bio (KYNB) Q1 2026 MANAGEMENT VIEW * CEO Thane Wettig said the quarter’s focus remained on “consistent progress we have made across our portfolio,” highlighting “FG-3246, our potential first-in-class anti... Full story

Yahoo Finance • 3 months ago

Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026

FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, taxane-naïve metastatic castration-resistant prostate cancer (mCRPC), led to a median radiographic prog... Full story